[Thrombolytic therapy of acute myocardial infarction]

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Acute myocardial infarction (AMI) is a leading cause of mortality.
• Thrombolytic therapy has proven effective in reducing AMI mortality when initiated early.
• Optimal management strategies for AMI remain an area of active research.

Purpose of the Study:

• To review the current evidence on thrombolytic therapy for acute myocardial infarction as of early 1995.
• To address complex aspects of thrombolytic therapy, including patient variability, timing, and agent selection.
• To provide a comprehensive overview of the state-of-the-art in AMI thrombolysis.

Main Methods:

• Literature review of existing studies on thrombolytic therapy for AMI.
• Analysis of evidence regarding the benefits and limitations of thrombolysis.
• Synthesis of data on different thrombolytic agents and administration protocols.

Main Results:

• Thrombolytic therapy administered within 12 hours of AMI onset reduces mortality.
• Benefits of thrombolysis may vary among different patient subgroups.
• Early administration is crucial for maximizing therapeutic effect.
• The value of late thrombolytic therapy requires further investigation.
• Optimal thrombolytic agent and mode of administration are critical considerations.

Conclusions:

• Thrombolytic therapy is a cornerstone in the management of acute myocardial infarction.
• Careful patient selection and timely administration are essential for optimal outcomes.
• Ongoing research is refining the use of thrombolytic agents and strategies.